• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ChREBP 在肝代谢紊乱中的因果和治疗动态。

Causative and Sanative dynamicity of ChREBP in Hepato-Metabolic disorders.

机构信息

School of Basic Sciences, Indian Institute of Technology Mandi, Mandi 175001, H.P, India.

出版信息

Eur J Cell Biol. 2020 Nov;99(8):151128. doi: 10.1016/j.ejcb.2020.151128. Epub 2020 Nov 2.

DOI:10.1016/j.ejcb.2020.151128
PMID:33232883
Abstract

ChREBP is the master regulator of carbohydrate dependent glycolytic and lipogenic flux within metabolic tissues. It plays a vital role in hyper-calorific milieu by activating glycolysis, lipogenesis along with pentose phosphate shunt and glycogen synthesis, fostering immediate reduction in the systemic glycemic levels. Liver being the primary organ to sense disproportionate dietary intake and linked physiological stress, stimulates ChREBP to perform the aforementioned processes. Activated ChREBP also inhibits lipolysis and encourages proper disposal of excessive triglycerides into adipocytes from the liver ablating hepatic intracellular lipid trafficking. Chronic overeating or onset of positive energy balance, hyper-activates ChREBP and signals development, intensification of hepato-metabolic disorders, and allied discrepancies in the whole-body metabolic functioning. ChREBP thus gets negatively connotated as the primary regulator of hepatic disorders, owing to its inherent features as the primary glycemic sensor and the only transcription factor that can transduce glucose-dependent glycolytic and lipogenic signals. Through this review, we - try to recapitulate and emphasize on the sanative events coordinated by ChREBP in several pathophysiological states. In totality, we aim to uncouple the disease-causing aspects of ChREBP from its positive attributes evoked during a metabolic crisis, in hepato-metabolic diseases.

摘要

ChREBP 是代谢组织中碳水化合物依赖性糖酵解和脂肪生成通量的主要调节因子。它在高热环境中通过激活糖酵解、脂肪生成以及戊糖磷酸途径和糖原合成发挥着至关重要的作用,有助于立即降低全身血糖水平。肝脏是感知饮食摄入不成比例和相关生理压力的主要器官,它会刺激 ChREBP 来执行上述过程。激活的 ChREBP 还会抑制脂肪分解,并鼓励肝脏将过多的甘油三酯适当处理为脂肪细胞,从而消除肝内脂质转运。长期暴饮暴食或出现正能 量平衡,会过度激活 ChREBP,并发出信号,导致肝代谢紊乱的发展和加剧,以及全身代谢功能的相关差异。因此,ChREBP 被负面地归因于肝障碍的主要调节因子,这归因于其作为主要血糖传感器和唯一可以转导葡萄糖依赖性糖酵解和脂肪生成信号的转录因子的固有特征。通过这篇综述,我们试图概括和强调 ChREBP 在几种病理生理状态下协调的治疗事件。总的来说,我们旨在将 ChREBP 在肝代谢疾病中的致病方面与其在代谢危机期间引发的积极属性区分开来。

相似文献

1
Causative and Sanative dynamicity of ChREBP in Hepato-Metabolic disorders.ChREBP 在肝代谢紊乱中的因果和治疗动态。
Eur J Cell Biol. 2020 Nov;99(8):151128. doi: 10.1016/j.ejcb.2020.151128. Epub 2020 Nov 2.
2
Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.肝碳水化合物反应元件结合蛋白激活限制糖原贮积病 1a 型小鼠模型中非酒精性脂肪性肝病的发展。
Hepatology. 2020 Nov;72(5):1638-1653. doi: 10.1002/hep.31198. Epub 2020 Oct 30.
3
The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans.脂肪生成转录因子 ChREBP 可使小鼠和人类的肝脂肪变性与胰岛素抵抗分离。
J Clin Invest. 2012 Jun;122(6):2176-94. doi: 10.1172/JCI41636. Epub 2012 May 1.
4
A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism.ChREBP 介导的 FGF21 分泌在肝脏果糖代谢中的关键作用。
Mol Metab. 2016 Nov 23;6(1):14-21. doi: 10.1016/j.molmet.2016.11.008. eCollection 2017 Jan.
5
Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice.ChREBP 与 SREBP-1c 之间的相互作用协调了小鼠肝脏餐后的糖酵解和脂肪生成。
J Lipid Res. 2018 Mar;59(3):475-487. doi: 10.1194/jlr.M081836. Epub 2018 Jan 15.
6
Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation.多不饱和脂肪酸通过抑制ChREBP核蛋白易位来抑制糖酵解和脂肪生成基因。
J Clin Invest. 2005 Oct;115(10):2843-54. doi: 10.1172/JCI25256. Epub 2005 Sep 22.
7
Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activity.Nogo 表达减少通过调节 ChREBP 和胰岛素活性抑制饮食诱导的代谢紊乱。
J Hepatol. 2020 Dec;73(6):1482-1495. doi: 10.1016/j.jhep.2020.07.034. Epub 2020 Jul 29.
8
The Protective Role of the Carbohydrate Response Element Binding Protein in the Liver: The Metabolite Perspective.糖反应元件结合蛋白在肝脏中的保护作用:代谢物视角。
Front Endocrinol (Lausanne). 2020 Nov 17;11:594041. doi: 10.3389/fendo.2020.594041. eCollection 2020.
9
ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome.ChREBP:一种参与代谢综合征发展的葡萄糖激活转录因子。
Endocr J. 2008 Aug;55(4):617-24. doi: 10.1507/endocrj.k07e-110. Epub 2008 May 19.
10
The absence of hepatic glucose-6 phosphatase/ChREBP couple is incompatible with survival in mice.肝葡萄糖-6-磷酸酶/ChREBP 偶联缺失与小鼠的生存不相容。
Mol Metab. 2021 Jan;43:101108. doi: 10.1016/j.molmet.2020.101108. Epub 2020 Oct 31.

引用本文的文献

1
Hepatic ChREBP reciprocally modulates systemic insulin sensitivity in NAFLD.肝脏中的碳水化合物反应元件结合蛋白(ChREBP)相互调节非酒精性脂肪性肝病(NAFLD)中的全身胰岛素敏感性。
J Biol Chem. 2025 Apr 29;301(6):108556. doi: 10.1016/j.jbc.2025.108556.
2
Application of PPAR Ligands and Nanoparticle Technology in Metabolic Steatohepatitis Treatment.过氧化物酶体增殖物激活受体配体与纳米颗粒技术在代谢性脂肪性肝炎治疗中的应用
Biomedicines. 2024 Aug 16;12(8):1876. doi: 10.3390/biomedicines12081876.
3
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Thyroid Function in Childhood Obesity: A Vicious Circle?
儿童肥胖中的代谢功能障碍相关脂肪性肝病(MAFLD)与甲状腺功能:恶性循环?
Children (Basel). 2024 Feb 15;11(2):244. doi: 10.3390/children11020244.
4
Rotundic acid improves nonalcoholic steatohepatitis in mice by regulating glycolysis and the TLR4/AP1 signaling pathway.圆山楂酸通过调控糖酵解和 TLR4/AP1 信号通路改善小鼠非酒精性脂肪性肝炎。
Lipids Health Dis. 2023 Dec 4;22(1):214. doi: 10.1186/s12944-023-01976-z.
5
Correlation of ChREBP Gene Methylation with Pathological Characteristics of Type 2 Diabetes Mellitus.ChREBP 基因甲基化与 2 型糖尿病病理学特征的相关性。
Appl Biochem Biotechnol. 2024 Jun;196(6):3076-3087. doi: 10.1007/s12010-023-04714-4. Epub 2023 Aug 24.
6
Thwarting Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) with Common Bean: Dose- and Sex-Dependent Protection against Hepatic Steatosis.用普通菜豆防治代谢相关脂肪性肝病(MAFLD):对肝脂肪变性的剂量和性别依赖性保护作用。
Nutrients. 2023 Jan 19;15(3):526. doi: 10.3390/nu15030526.
7
Liver Steatosis: A Marker of Metabolic Risk in Children.肝脂肪变性:儿童代谢风险的标志物。
Int J Mol Sci. 2022 Apr 27;23(9):4822. doi: 10.3390/ijms23094822.
8
NF-κB p65 regulates hepatic lipogenesis by promoting nuclear entry of ChREBP in response to a high carbohydrate diet.NF-κB p65 通过促进 ChREBP 入核来调节肝内脂质生成,以响应高碳水化合物饮食。
J Biol Chem. 2021 Jan-Jun;296:100714. doi: 10.1016/j.jbc.2021.100714. Epub 2021 Apr 27.